Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Jun;87(6):2029-35.
doi: 10.1172/JCI115232.

Rearrangements of the tal-1 locus as clonal markers for T cell acute lymphoblastic leukemia

Affiliations

Rearrangements of the tal-1 locus as clonal markers for T cell acute lymphoblastic leukemia

O G Jonsson et al. J Clin Invest. 1991 Jun.

Abstract

Normal and aberrant immune receptor gene assembly each produce site-specific DNA rearrangements in leukemic lymphoblasts. In either case, these rearrangements provide useful clonal markers for the leukemias in question. In the t(1;14)(p34;q11) translocation associated with T cell acute lymphoblastic leukemia (T-ALL), the breakpoints on chromosome 1 interrupt the tal-1 gene. A site-specific deletion interrupts the same gene in an additional 26% of T-ALL. Thus, nearly one-third of these leukemias contain clustered rearrangements of the tal-1 locus. To test whether these rearrangements can serve as markers for residual disease, we monitored four patients with T-ALL; three of the leukemias contained a deleted (tald) and one a translocated (talt) tal-1 allele. These alleles were recognized by a sensitive amplification/hybridization assay. tald alleles were found in the blood of one patient during the 4th mo of treatment but not thereafter. Using a quantitative assay to measure the fraction of tald alleles in DNA extracts, we estimated that this month 4 sample contained 150 tald copies per 10(6) genome copies. The patient with t(1;14)(p34;q11) (talt) leukemia developed a positive assay during the 20th mo of treatment. By standard criteria, all four patients remain in complete remission 11-20 mo into treatment. We conclude that tal-1 rearrangements provide useful clonal markers for approximately 30% of T-ALLs.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Blood. 1990 Jan 1;75(1):166-73 - PubMed
    1. Leukemia. 1989 Dec;3(12):886-92 - PubMed
    1. Proc Natl Acad Sci U S A. 1990 Jan;87(2):563-7 - PubMed
    1. Cell. 1990 Feb 23;60(4):535-45 - PubMed
    1. Cell. 1990 Feb 23;60(4):547-55 - PubMed

Publication types